D. Boral Capital Lowers Quince Therapeutics (NASDAQ:QNCX) Price Target to $4.00

Quince Therapeutics (NASDAQ:QNCX) had its target price cut by stock analysts at D. Boral Capital from $12.00 to $4.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. D. Boral Capital’s target price suggests a potential upside of 198.51% from the stock’s current price.

Several other analysts also recently commented on the company. Brookline Capital Management assumed coverage on Quince Therapeutics in a research note on Wednesday, December 18th. They issued a “buy” rating and a $9.00 price objective for the company. Oppenheimer began coverage on shares of Quince Therapeutics in a report on Monday. They issued an “outperform” rating and a $10.00 target price for the company. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $8.00.

Quince Therapeutics Price Performance

Shares of NASDAQ:QNCX opened at $1.34 on Tuesday. The stock’s 50 day moving average is $1.48 and its 200-day moving average is $1.44. Quince Therapeutics has a twelve month low of $0.51 and a twelve month high of $2.45. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $58.96 million, a price-to-earnings ratio of -1.08 and a beta of 0.71.

Quince Therapeutics (NASDAQ:QNCX) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.09). The firm had revenue of $0.17 million for the quarter. Sell-side analysts forecast that Quince Therapeutics will post -1.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Quince Therapeutics

Several institutional investors have recently added to or reduced their stakes in QNCX. Geode Capital Management LLC grew its position in shares of Quince Therapeutics by 24.2% during the 3rd quarter. Geode Capital Management LLC now owns 339,125 shares of the company’s stock valued at $263,000 after acquiring an additional 66,170 shares during the period. Scharf Investments LLC bought a new stake in Quince Therapeutics in the 4th quarter valued at about $170,000. Anfield Capital Management LLC purchased a new stake in Quince Therapeutics during the fourth quarter valued at about $50,000. Virtu Financial LLC purchased a new position in shares of Quince Therapeutics in the fourth quarter worth about $55,000. Finally, Northern Trust Corp raised its position in shares of Quince Therapeutics by 48.5% in the fourth quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock valued at $94,000 after purchasing an additional 16,501 shares during the period. Institutional investors own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.